Randomised, double-blind, placebo-controlled trial of EPs 7630 in adults with COPD

Respiratory Medicine

Volumn 107, Issue 5, 2013, Pages 691-701

  Matthys, Heinrich ^a   Pliskevich, Dina A ^b   Bondarchuk, Oleksandr M ^b   Malek, Fathi A ^c   Tribanek, Michael ^c   Kieser, Meinhard ^d  

^a UNIVERSITY OF FREIBURG   (Germany)

^b BOGOMOLETS NATIONAL MEDICAL UNIVERSITY   (Ukraine)

^c DR WILLMAR SCHWABE GMBH AND CO KG   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

COPD; Efficacy; EPs 7630; Exacerbations; Herbal drug preparation; Pelargonium sidoides

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BUDESONID; BUDESONIDE; FENOTEROL PLUS IPRATROPIUM BROMIDE; OFLOXACIN; PELARGONIUM SIDOIDES EXTRACT; PLACEBO; PREDNISOLONE; SALMETEROL; SALMETEROL XINAFOATE; UNCLASSIFIED DRUG;

ADD ON THERAPY; ADULT; ANTIBIOTIC THERAPY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; WORK DISABILITY;

ACUTE DISEASE; ADULT; AGED; ANTI-INFECTIVE AGENTS; COMORBIDITY; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; PHYTOTHERAPY; PLANT EXTRACTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY SYSTEM AGENTS; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84876043599     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2013.02.011     Document Type: Article

References (40)

1. Global Initiative for Chronic Obstructive Lung Disease Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2009 Executive summary. [cited 2010 Feb 5]. Available from: http://www.goldcopd.com/download.asp?intId=555
2. National Guideline Clearinghouse. Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. [cited 2010 Feb 5]. Available from: http://www.guideline.gov/summary/summary.aspx?doc-id=5061&nbr= 003545&string=copd.
3. R.J. Halbert, J.L. Natoli, A. Gano, E. Badamgarav, A.S. Buist, and D.M. Mannino Global burden of COPD: systematic review and meta-analysis Eur Respir J 28 2006 523 532
4. B.R. Celli, R.J. Halbert, R.J. Nordyke, and B. Schau Airway obstruction in never smokers: results from the Third National Health and Nutrition Examination Survey Am J Med 118 2005 1364 1372
5. J. Balmes, M. Becklake, P. Blanc, P. Henneberger, K. Kreiss, and C. Mapp American Thoracic Society Statement: occupational contribution to the burden of airway disease Am J Respir Crit Care Med 167 2003 787 797
6. M.D. Eisner, J. Balmes, P.P. Katz, L. Trupin, E.H. Yelin, and P.D. Blanc Lifetime environmental tobacco smoke exposure and the risk of chronic obstructive pulmonary disease Environ Health 4 2005 7
7. K.R. Smith, S. Mehta, and M. Maeusezahl-Feuz Indoor air pollution from household use of solid fuels M. Ezzati, A.D. Lopez, A.A. Rodgers, C.J.L. Murray, Comparative quantification of health risks: global and regional burden of disease attributable to selected major risk factors 2004 World Health Organization Geneva 1435 1493
8. A. Anzueto Impact of exacerbations on COPD Eur Respir Rev 19 2010 113 118
9. C. Vogelmeier, R. Buhl, C.P. Criée, A. Gillissen, P. Kardos, and D. Köhler Leitlinie der Deutschen Atemwegsliga und der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin zur Diagnostik und Therapie von Patienten mit chronisch obstruktiver Bronchitis und Lungenemphysem (COPD). Guidelines for the diagnosis and therapy of COPD issued by Deutsche Atemwegsliga and Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin Pneumologie 61 2007 e1 e40
10. H. Kolodziej, O. Kayser, O.A. Radtke, A.F. Kiderlen, and E. Koch Pharmacological profile of extracts of Pelargonium sidoides and their constituents Phytomedicine 10 Suppl. 4 2003 18 24
11. ® 7630) inhibits the interactions of group A-streptococci and host epithelia in vitro Phytomedicine 14 Suppl. 6 2007 52 59
12. ® 7630) improves phagocytosis, oxidative burst, and intracellular killing of human peripheral blood phagocytes in vitro Phytomedicine 14 Suppl. 6 2007 46 51
13. ® 7630 Phytomedicine 14 Suppl. 6 2007 18 26
14. ®) Naunyn-Schmiedeberg's Arch Parmacol 365 Suppl. 1 2002 R75
15. ® 7630) in mice Phytomedicine 14 Suppl. 6 2007 27 31
16. T.B. Agbabiaka, R. Guo, and E. Ernst Pelargonium sidoides for acute bronchitis: a systematic review and meta-analysis Phytomedicine 15 2008 378 385
17. ®) bei Sinusitis Z Phytother 28 2007 58 65
18. C. Bachert, A. Schapowal, P. Funk, and M. Kieser Treatment of acute rhinosinusitis with the preparation from Pelargonium sidoides EPs 7630: a randomized, double-blind, placebo-controlled trial Rhinology 47 2009 51 58
19. V.G. Lizogub, D.S. Riley, and M. Heger Efficacy of a Pelargonium sidoides preparation in patients with the common cold: a randomized, double blind, placebo-controlled clinical trial Explore 3 2007 573 584
20. American Association for Respiratory Care (AARC) AARC clinical practice guideline. Spirometry, 1996 update Respir Care 41 1996 629 636
21. J. Roca, F. Burgos, J. Sunyer, M. Saez, S. Chinn, J.M. Antó for the Group of the European Community Respiratory Health Survey References values for forced spirometry Eur Respir J 11 1998 1354 1362
22. P. Bauer, and K. Köhne Evaluation of experiments with adaptive interim analyses Biometrics 50 1994 1029 1041
23. T.A. Seemungal, G.C. Donaldson, E.A. Paul, J.C. Bestall, D.J. Jeffries, and J.A. Wedzicha Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease Am J Respir Crit Care Med 157 1998 1418 1422
24. M. Cazzola, W. MacNee, F.J. Martinez, K.F. Rabe, L.G. Franciosi, and P.J. Barnes Outcomes for COPD pharmacological trials: from lung function to biomarkers Eur Respir J 31 2008 416 468
25. P.W. Jones, F.H. Quirk, C.M. Baveystock, and P. Littlejohns A self-complete measure of health status for chronic airflow limitation: the St. George's Respiratory Questionnaire Am Rev Respir Dis 145 1992 1321 1327
26. J.D. Kalbfleisch, and R.L. Prentice The statistical analysis of failure time data 1980 John Wiley New York
27. D.M. Halpin Lessons from the major studies in COPD: problems and pitfalls in translating research evidence into practice Prim Care Resp J 19 2 2010 170 179
28. T. Pertseva, and O. Myronenko The comparative characteristic of respiratory muscles function in patients with bronchial obstruction Eur Respir J 38 Suppl. 55 2011 80s
29. H. Demchuk, and Y. Mostovoy Analysis of therapy of community-acquired pneumonia (CAP) at the COPD patients Eur Respir J 38 Suppl. 55 2011 77s
30. S. Burge, and J.A. Wedzicha COPD exacerbations: definitions and classifications Eur Respir J 21 2003 46S 53S
31. S.S. Salvi, and P.J. Barnes Chronic obstructive pulmonary disease in non-smokers Lancet 374 2009 733 743
32. Tobacco use in Ukraine: most recent national survey(s) for chronic, noncommunicable disease risk factors. WHO Global InfoBase. [cited 2010 Feb 5]. Available from: http://www.who.int/infobase/reportviewer.aspx?uncode= 804&rptcode=BCP&dm=8&print=1.
33. M. Ezzati Indoor air pollution and health in developing countries Lancet 366 2005 104 106
34. P.M. Calverley Minimal clinically important difference-exacerbations of COPD COPD 2 2005 143 148
35. A.-B. Tonnel, T. Perez, J.-M. Grosbois, C. Verkindre, M.-L. Bravo, and M. Brun Effect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD Int J Chron Obstruct Pulmon Dis 3 2008 301 310
36. P.W. Jones St. George's respiratory questionnaire: MCID COPD 2 2005 75 79
37. W. Kamin, V.G. Maydannik, F.A. Malek, and M. Kieser Efficacy and tolerability of EPs 7630 in patients (aged 6-18 years old) with acute bronchitis: a randomized, double-blind, placebo-controlled clinical dose-finding study Acta Paediatr 99 2010 537 543
38. W. Kamin, V. Maydannik, F.A. Malek, and M. Kieser Efficacy and tolerability of EPs 7630 in children and adolescents with acute bronchitis: a randomized, double-blind, placebo-controlled multicenter trial with a herbal drug preparation from Pelargonium sidoides roots Int J Pharmacol Ther 48 2010 184 191
39. H. Matthys, V.G. Lizogub, F.A. Malek, and M. Kieser Efficacy and tolerability of EPs 7630 tablets in patients with acute bronchitis: a randomised, double-blind, placebo-controlled dose-finding study with a herbal drug preparation from Pelargonium sidoides Curr Med Res Opin 26 2010 1413 1422
40. H. Matthys, and P. Funk EPs 7630 improves acute bronchitic symptoms and shortens time to remission. Results of a randomised, double-blind, placebo-controlled, multicentre trial Planta Med 74 2008 686 692